SCHEMBL31161491

SCHEMBL31161491

CC(C)(C)OC(=O)N1CCN(C2CCN(C(=O)c3ccc(Cl)c(N4CCC(=O)NC4=O)c3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ LRRK2 Q5S007 1/20 0.43
▸ PDK1 Q15118 1/20 0.42
▸ PDK2 Q15119 1/20 0.42
▸ PDK3 Q15120 1/20 0.42
▸ PDK4 Q16654 1/20 0.42
▸ CRBN Q96SW2 7/20 0.42
▸ DDB1 Q16531 6/20 0.42
▸ ABL1 P00519 1/20 0.40
▸ RIN1 Q13671 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL3 Q96JM7 3/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ TRPV6 Q9H1D0 1/20 0.39
▸ ACACB O00763 1/20 0.39
▸ ACACA Q13085 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161778 1.00 MEN1 (0.45) MEN1KMT2ALRRK2PDK1PDK2
SCHEMBL26100969 0.92 MEN1 (0.43) MEN1KMT2APDK1PDK2PDK3
SCHEMBL26099471 0.92 MEN1 (0.52) MEN1KMT2APDK1PDK2PDK3
SCHEMBL23121362 0.90 KMT2A (0.44) MEN1KMT2APDK1PDK2PDK3
SCHEMBL29892557 0.88 GPR119 (0.43) MEN1KMT2APDK1PDK2PDK3
SCHEMBL23123648 0.87 CNR1 (0.43) MEN1KMT2APDK1PDK2PDK3
SCHEMBL31161308 0.87 CNR1 (0.43) MEN1KMT2APDK1PDK2PDK3
SCHEMBL31024364 0.87 MEN1 (0.42) MEN1KMT2APDK1PDK2PDK3
SCHEMBL27124609 0.87 MEN1 (0.42) MEN1KMT2APDK1PDK2PDK3
SCHEMBL31161368 0.87 MEN1 (0.39) MEN1KMT2ALRRK2PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 MEN1 4258/4885KMT2A 242/4885LRRK2 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback